Aruvant Taps Sarepta’s Palaniappan as Chief Technology Officer

Aruvant Sciences has appointed V. “Palani” Palaniappan to serve as chief technology officer. He comes to the clinical-stage gene therapy developer from Sarepta Therapeutics (NASDAQ: [[ticker:SRPT]]), where he was senior vice president and head of technical operations. His experience also includes positions at Takeda Pharmaceutical (NASDAQ: [[ticker:TAK]]), Millennium Pharmaceuticals, Biogen (NASDAQ: [[ticker:BIIB]]), and Nexstar Pharmaceuticals.

Aruvant, a subsidiary of Roivant Sciences, maintains operations in New York and Basel, Switzerland. The company’s lead candidate is ARU-1801, a gene therapy being developed to treat two blood disorders, sickle cell disease and beta thalassemia.

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times. View all posts by Frank Vinluan